1. Introduction {#s0005}
===============

The SARS-CoV-2 responsible for the COVID-19 pandemic is a new coronavirus of the subgenus *Sarbecovirus* ([@b0060]). Like SARS-CoV, the SARS-CoV-2 is an Angiotensin I converting enzyme 2 (ACE2)-tropic virus, and the "spike" (S) protein of the viral envelope would thus bind to the nasopharyngeal mucosa and alveolar pneumocytes that express ACE2 at their surface ([@b0195], [@b0150], [@b0075]). The clinical spectrum of this disease, termed COVID-19, ranges from mild to very severe cases ([@b0055], [@b0140]). It has been hypothesized that viral infection drives an exacerbated inflammatory response, leading to severe lung injury that may require ICU admission, mechanical ventilation and increases the risk of multi-organ failure and death ([@b0095]).

The Renin-Angiotensin-Aldosterone system (RAAS) seems to play an important role in the pathogenesis of COVID-19 ([@b0085]). The angiotensin-converting enzyme (ACE or ACE1) catalyzes the synthesis of Angiotensin-II (Ang-II) from Ang-I, and ACE2 hydrolyzes Ang-II into Ang-1--7. Ang-II binds to the AT1-receptor driving vasoconstriction, fibrosis, inflammation, thrombosis, among other responses; while Ang-1--7 binds to the AT2-receptor with increased vasodilation and reduced fibrosis, inflammation, and thrombosis. The ACE and ACE2 are thus seen as opposite players in the balance that determines the risk of developing hypertension and cardiovascular disease. In the lung, ACE2 drives a protective response by reducing oedema, permeability and pulmonary damage ([@b0080], [@b0020], [@b0015], [@b0105]). Of note, hypertension and cardiovascular disease are frequent comorbidities in COVID-19, and are strongly associated with the risk of hospitalization and death in individuals exposed to SARS-CoV-2 ([@b0205], [@b0065], [@b0155], [@b0025]).

Both, acquired and inherited factors associated with differences in the expression and function of the RAAS components could explain the risk of developing COVID-19 and adverse events. For instance, ACE2 expression in the lungs markedly decreases with age and is greater in men than in women ([@b0185]). This could explain the higher risk for adverse outcomes in elderly and male. In general, conditions related with a reduced ACE2 expression would increase the risk for hypertension, cardiac hypertrophy, and heart failure ([@b0135], [@b0115]). In opposition, a high activity of ACE would increase the risk of lung and cardiovascular disease by increased activity of the Ang-II/AT1R axis. Common variants in the two *ACE* genes have been associated with the risk of hypertension, heart disease, renal failure, and pulmonary disease. In fact, the *ACE* insertion/deletion (I/D) is one of the best characterised human polymorphisms. Individuals with a D/D genotype showed the highest blood ACE levels, and this increased expression would explain the higher risk for cardiovascular and respiratory disease among individuals who are deletion-homozygous. This polymorphism has been related with the outcome in acute respiratory distress syndrome (ARDS) by some authors, and also with the progression of pneumonia in SARS ([@b0120], [@b0125], [@b0165], [@b0090]).

The *ACE2* gene is on chromosome X and several single nucleotide polymorphisms (SNPs) have been investigated as risk factors for hypertension and heart failure, including a G to A change at nucleotide + 4 of intron 3 (SNP rs2285666) ([@b0160], [@b0200], [@b0110], [@b0035]). The fact that *ACE2* is on chromosome X has been seen as a disadvantage for male carriers of alleles linked to a lower ACE2 expression, and could explain the higher prevalence of severe COVID-19 among males. SARS-CoV down-regulates myocardial ACE2 expression and this could explain the myocardial inflammation and damage and adverse cardiac outcomes in patients with SARS ([@b0130]).

Our current knowledge supports a role for the ACE/ACE2 imbalance in the pathogenesis of COVID-19. In this context, variants at these genes associated with differences in gene expression and protein function might explain the individuaĺs predisposition to manifest the disease symptoms and the risk for hospitalization and adverse events. Moreover, some authors have hypothesised that regional differences in allele frequencies could explain the different rate of the incidence and mortality ([@b0190], [@b0050], [@b0045], [@b0030], [@b0070]).

Our purpose was to determine whether two common functional *ACE* and *ACE2* variants were associated with susceptibility and outcome in COVID-19.

2. Patients and methods {#s0010}
=======================

2.1. Study cohorts {#s0015}
------------------

We collected the anthropometric and clinical data of 204 patients who required hospitalization due to COVID-19 (mean age 64.77 years, range 24--95). All the study participants were Caucasian from the region of Asturias (Northern Spain, total population 1 million), and positive for SARS-Cov-2 (PCR test from nasal swabs or tracheobronchial aspirates). Severe cases (n = 67) were defined as those in need of critical care support, including high-flow oxygen, positive-pressure ventilation (either invasive or non-invasive) or vasoactive drugs. We also studied 536 healthy population controls matched with the patients for age (n = 536; mean age 70.01 years, range 50--81). The presence of comorbidities (hypertension, diabetes, hypercholesterolaemia) was obtained from the participants medical records. The study was approved by the Ethics Committee of Principado de Asturias (Oviedo, Spain). All the patients or their representatives gave their consent to participate.

2.2. Genotyping {#s0020}
---------------

The I/D polymorphism (rs4646994) in intron 16 of the *ACE* gene was genotyped by polymerase chain reaction (PCR) followed by agarose gel electrophoresis to visualise the two alleles, as reported ([@b0005], [@b0010], [@b0040]). For the *ACE2* rs2285666 A/G SNP the PCR fragments were digested with the restriction enzyme *AluI* and electrophoresis on agarose gels ([Suppl. figures](#s0065){ref-type="sec"}).

2.3. *ACE2* sequencing {#s0025}
----------------------

The *ACE2* coding exons of 60 male patients (30 severe and 30 non-severe) were amplified with primers designated from exon flanking introns ([Suppl. Table 1](#s0065){ref-type="sec"}). These fragments were sequenced with Sanger BigDye chemistry in a capillary ABI3130xl equipment, and the sequences for each patient compared with the *ACE2* reference sequence ([www.ensembl.org](http://www.ensembl.org){#ir005}).

2.4. Statistical analysis {#s0030}
-------------------------

All the patients and controls data were collected in an excel file and following the requirements of the Ethical Committee. The statistical analysis was performed with the R-project free software ([www.r-project.org](http://www.r-project.org){#ir010}). The logistic regression (linear generalized model, LGM) was used to compare mean values and frequencies between the groups.

3. Results {#s0035}
==========

Compared to age-matched controls, patients with COVID-19 did not differ in the frequency of diabetes, hypertension, and the *ACE*-DD genotype ([Table 1](#t0005){ref-type="table"} ). We found a non-significantly lower frequency of hypercholesterolemia in the patients. We compared these variables in severe COVID-19 (patients who required mechanical ventilation and/or ICU supportive care) and mild-disease patients. Male sex, hypertension, hypercholesterolemia, and the *ACE*-DD genotype frequencies were significantly higher in the severe group ([Table 1](#t0005){ref-type="table"}). The multiple logistic regression-LGM showed that hypertension (p = 0.02; OR = 2.26, 95%CI = 1.12--4.63) and male gender (p = 0.002; OR = 3.15, 95%CI = 1.56--6.66) remained as independent significant predictors of severity.Table 1Main clinical values and genotype frequencies in total patients and controls.Severe Disease\
N = 67MildDisease\
N = 137pAll COVID\
N = 204Controls\
N = 536pMean age65.7664.560.5364.9669.88AVMale53 (79%)72 (53%)\<0.001125 (61%)248 (46%)AVHypertensives41 (61%)56 (41%)0.00697 (48%)228 (43%)0.22Diabetes15 (22%)21 (15%)0.2136 (18%)123 (23%)0.13Hyperchols29 (43%)40 (29%)0.04669 (34%)220 (41%)0.07*ACE I/D*DD31 (46%)44 (32%)0.049\*75 (37%)195 (36%)0.92\*ID31 (46%)76 (56%)107 (52%)256 (48%)II5 (8%)17 (12%)22 (11%)85 (16%)*ACE2*\#A-carriers52 (78%)94 (69%)0.18146 (72%)374 (75%)0.33G15 (22%)43 (31%)58 (28%)124 (25%)[^1][^2]

We then compared the values in men and women. In men, hypertension, hypercholesterolemia and the *ACE*-DD were significantly increased in severe patients ([Table 2](#t0010){ref-type="table"} ). The *ACE2* rs2285666 alleles did not differ between the two patients groups and were non-significantly higher to the control frequencies. The same analysis performed among female patients revealed no differences between the severe and mild cases, although we observed a trend toward a higher risk for severity among hypertension and hypercholesterolaemia, and a non-significantly higher frequency of the A-allele in the two patients groups compared to controls ([Suppl. Table 2](#s0065){ref-type="sec"}). The results in this female cohort would be limited by the reduced size of the severe cases (n = 14).Table 2Values in the male patients and controls.MaleSevere\
N = 53Mild\
N = 72pCovid\
N = 125Control\
N = 248pMean age67.1963.890.1364.7770.01AVHypertensives34 (64%)26 (36%)0.00260 (48%)97 (39%)0.10Diabetics12 (23%)12 (17%)0.4224 (19%)47 (19%)1Hiperlchols25 (47%)18 (25%)0.0143 (34%)82 (33%)0.79ACE2\#G43 (81%)58 (81%)0.92101 (81%)200 (85%)0.25A10 (19%)14 (19%)24 (19%)34 (15%)ACE I/DDD28 (53%)25 (35%)0.043\*53 (42%)85 (34%)0.13ID23 (43%)43 (60%)66 (53%)123 (50%)II2 (4%)4 (5%)6 (5%)40 (16%)[^3][^4]

To better understand the relationship between the two ACE polymorphisms and hypertension, we compared the genotype frequencies between hypertensives and normotensives in male and female patients and controls ([Fig. 1](#f0005){ref-type="fig"} ; [Suppl. Table 3](#s0065){ref-type="sec"}). In males, the ACE-DD genotype had a higher frequency among hypertensives in the three groups, without statistically significant differences. The *ACE2*-A allele was significantly increased in the hypertensive controls (21% vs. 10%; p = 0.02), with no significant differences between severe and non-severe COVID-19 cases. In the female cohort, the DD frequencies did not differ between hypertensive and normotensive in the three groups. The rs2285666 A allele was significantly more frequent among the hypertensive controls (p = 0.04). These results suggested that the *ACE*-DD genotype and *ACE2*-A carriers could be at a higher risk for hypertension in our population, and genotype and allele differences between the severe and non-severe COVID-19 cases could be attribute to their association with hypertension.Fig. 1Frequencies of *ACE-*DD and *ACE2* rs2285666 A-carriers according to hypertension in COVID-19 patients and population controls. HT = hypertensives, NT = normotensives.

We sequenced the ACE2 coding and immediate intronic flanking regions in a group of patients, and the only variant identified was rs2285666. This suggested a very low genetic variability in the SARS-CoV-2 receptor, and a significant absence of common variants that could increase the risk for infection in our population.

4. Discussion {#s0040}
=============

Since the outbreak of the COVID-19 pandemic several authors have speculated about the role of the *ACE* and *ACE2* gene polymorphisms in disease susceptibility and severity. Because ACE2 is the SARS-CoV-2 receptor, a functional variant that increased gene expression could be associated with a higher number of membrane-bound viral binding sites, increasing the vulnerability of carriers to infection. These risk variants might be particularly adverse in males, who carry only one copy of X-linked *ACE2* gene. The *ACE2* rs2285666 SNP was in the intronic-consensus splicing nucleotides and could thus affect the processing of *ACE2* total RNA to mRNA and, eventually, the amount of the protein. At least one study has reported higher levels of circulating ACE2 levels in men than in women ([@b0145]). One study has investigated the effect of rs2285666 on serum ACE2 levels, and found significantly higher levels in A-carriers compared to G-homozygotes ([@b0175]). A different intronic SNP in strong linkage disequilibrium with rs2285666 (rs879922) has been associated with *ACE2* gene expression ([@b0200]). We thus hypothesised that these functional *ACE2* variants could modify the disease outcome. In our study, the A-allele frequency was non-significantly higher in patients vs. controls but was associated with hypertension in both, male and female controls. Lower *ACE2* levels should be harmful for patients with lung disease, and the frequency observed in COVID-19 patients could thus be the balance between the negative association with viral infection (lower expression in the airway epithelia) and a positive association with respiratory and cardiovascular disease (lower expression in lung and other organs).

The *ACE2* A allele has frequencies of 0.15 and 0.19 in our elderly controls. According to the human gene variation databases, this frequency is lower that the reported among unselected Caucasians (0.20--0.25) including the Spanish population (0.24). This lower frequency could be characteristic of our population, but might also reflect a reduction of the lifespan for rs2285666 A carriers.

Functional variants in receptors for other viruses confer resistance to infection. One the best characterised is CCR5, the cellular receptor for HIV. A common variant that determines the absence of the receptor (CCR5-Δ32) confers a complete resistance to HIV-infection among homozygotes, while reduces the disease progression in heterozygotes. Approximately 1% of the Caucasians are *CCR5*-Δ32 homozygotes and they have a non-significant reduction in lifespan ([@b0005], [@b0010]). On the contrary, *ACE2* pathogenic variants are very rare at a population scale, and the complete absence of the receptor would be incompatible with life in humans. Moreover, according to the human genome variation databases, there are no common missense changes in the coding *ACE2* sequence. At a minor allele frequency \> 0.01% only four missense changes have been reported (all with global frequencies \< 1%), and rs2285666 was the only variant that could affect splicing ([Suppl. Table 4](#s0065){ref-type="sec"}). We sequenced the exon and intron-flanking sequence in 60 patients and rs2285666 was the only identified variant. Therefore, it is unlikely that the *ACE2* coding variants have a significant effect on susceptibility to SARS-CoV-2 infection. Of course, this does not exclude that variants in other gene regions are related with gene expression and the amount of protein.

ACE2 expression is regulated by Ang-II through the AT1R-pathway ([@b0100], [@b0180]). ACE could thus modulate the ACE2 expression and activity through the regulation of Ang-II levels. In this scenario the *ACE2* gene might be down-regulated in *ACE1*-DD homozygotes, who have increased ACE activity. There are two mechanisms by which functional *ACE* variants could modulate the risk of developing and the clinical outcome of SARS-CoV-2 infection. The reduction of *ACE2* expression could protect against viral infection but would also reduce the beneficial effect of *ACE2* in the lung and other organs. At the same time, *ACE* would enhance the deleterious Ang-II/AT1R response. The *ACE*-DD has been associated with and increased risk of respiratory distress system by some authors, but not confirmed by others ([@b0125], [@b0165], [@b0090]). This polymorphism was investigated in 44 Vietnamese SARS cases and 103 healthy controls who had been exposed to SARS-CoV and 50 controls without contact with SARS-patients (non-exposed) ([@b0090]). There were no significant differences for DD-frequency among the groups, suggesting that this polymorphism has no effect on the risk for SARS-CoV infection. However, the frequency of the D allele was significantly higher in hypoxemic than in the non-hypoxemic patients, and could thus contribute to the progression of pneumonia in SARS. In our study we did not find differences for DD-frequencies between COVID-19 and controls, thus confirming the lack of association with the risk of developing COVID-19 symptoms. However, we did not study individuals exposed who remained asymptomatic and we could thus not exclude an effect in the resistance to viral infection. We found a significant higher risk for a severe form of COVID-19 in males. This association was not found among females, although the number of severe-disease women was very low (n = 14). We confirmed that this genotype was associated with the risk for hypertension in our male controls, with a trend for association with hypertension in the patients. Thus, we concluded that the deleterious effect of the *ACE* polymorphism on COVID-19 outcome was likely due to its association with hypertension.

Our study has several limitations, mainly the reduced sample size of the patients and of female severe cases in particular. This limits the statistical interpretation of the significant and non-significant associations. Also, we did not study subjects exposed to the virus who did not show disease symptoms. These individuals would be resistant to SARS-CoV-2 infection and are crucial for the identification of gene variants associated with disease susceptibility.

In conclusion, our study suggested that the *ACE*-ID polymorphism was associated with the risk of developing severe COVID-19 depending on the hypertension status. The *ACE2* rs2285666 variant was associated with hypertension in our elderly population, without significant difference between mild and severe COVID-19 patients.
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[^1]: AV: adjust variable, \#498 controls genotyped, A-carriers = male A and female AA + AG.

[^2]: \* DD vs ID + II.

[^3]: AV: adjust variable, \#234 male controls genotyped.

[^4]: \* DD vs ID + II.
